Login to Your Account

United Therapeutics Remodulin Deal

Handy Aradigm Inhaler Key To PAH Prostacyclin Usage?

By Randall Osborne

Monday, September 10, 2007
Last week s new deal between Aradigm Corp. and existing partner United Therapeutics Corp. through its wholly owned subsidiary Lung Rx Inc. to develop Remodulin (treprostinil) using the former s AERx Essence approach could provide the needed boost to put prostacyclins at the forefront of pulmonary arterial hypertension therapy (PAH), thanks to the metered-dose inhaler.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription